If you spend any time reading about hair loss online, you have probably run into confident-sounding claims about stem cell therapy, exosomes, "cutting-edge peptides," or new drugs that will replace the medications people have been using for the last 30 years. Some of this coverage is reasonable. Most of it overstates how close any given approach is to actually being available, and how strong the evidence behind it really is. This guide walks through the categories of hair loss research that come up most often, what the published data actually shows, and how to think about them in the context of the treatments that already have decades of clinical track record behind them.
A useful framing before diving in: research stages move slowly for good reason. A treatment that shows a signal in mice is not the same as one with a phase 2 trial result, which is not the same as one with phase 3 data, which is not the same as one that is FDA-approved for hair loss. Most of the items below are at earlier stages than the marketing around them implies.
Where the standard of care sits today
The two medications with the largest evidence bases for pattern hair loss are still topical minoxidil and oral finasteride. Both have multiple decades of randomized trial data, head-to-head comparisons, and post-marketing experience in millions of patients. The mechanisms are covered in detail in how minoxidil treats hair loss and how finasteride treats hair loss. Oral dutasteride is a third option with a stronger effect size for some patients, covered in how dutasteride treats hair loss.
When evaluating an experimental treatment, the relevant comparison is not "does it grow some hair" but "does it grow more hair than these existing medications, with a comparable or better safety profile, at a price patients can sustain." Most of the candidates below have not yet been compared against the standard of care in adequate trials.
JAK inhibitors
JAK inhibitors are oral or topical medications that block Janus kinase enzymes involved in immune signaling. Two of them, baricitinib and ritlecitinib, are now FDA-approved for severe alopecia areata, the autoimmune form of hair loss that produces patchy or total scalp shedding. The BRAVE-AA pivotal trials of baricitinib showed roughly 35% of patients achieving 80% or more scalp coverage at 36 weeks on the higher dose, compared with around 5% on placebo (King et al., N Engl J Med, 2022). Ritlecitinib produced similar response rates in the ALLEGRO trials (King et al., Lancet, 2023).
This is meaningful, but it is also narrow. Alopecia areata is a different disease from androgenetic alopecia (pattern hair loss), and the published JAK inhibitor data does not show the same effect in pattern hair loss. Off-label use for pattern hair loss is occasionally reported in case series, but the systemic safety profile of these drugs (which includes warnings about serious infections, thrombosis, and malignancy) makes them a poor risk-benefit fit for a benign condition like pattern hair loss when minoxidil and finasteride exist. The reasonable summary is: a real advance for alopecia areata, not currently a viable option for the much more common pattern hair loss.
Stem cell and regenerative approaches
"Stem cell therapy for hair loss" covers a wide range of approaches with very different evidence levels. Some clinics market injections of stromal vascular fraction, adipose-derived cells, or platelet-rich plasma (PRP) as "stem cell" treatments, which is a loose use of the term. PRP itself has a moderate evidence base as an adjunctive treatment, with several small randomized trials showing modest density improvements when injected on a maintenance schedule. The effect size is smaller than oral finasteride and the protocols vary widely between clinics.
True follicle regeneration, growing new follicles from cultured cells rather than supporting existing ones, has been a research goal for decades. Companies and academic labs have demonstrated proof-of-concept in mouse and pig models, but no approach has yet shown reliable, durable hair growth from de novo follicles in humans at clinical scale. Treatments offered today under labels like "stem cell hair restoration" are generally PRP or related injections marketed at a premium. If a clinic is offering a "stem cell" treatment for a few thousand dollars, it is almost certainly not what the underlying research literature means by stem cell therapy.
Exosomes
Exosomes are small membrane-bound vesicles secreted by cells that carry signaling proteins and RNA. The idea behind exosome therapy is that vesicles derived from stem cells or other tissues can deliver pro-growth signals to scalp follicles when injected or applied topically. Several small case series have reported density improvements, and the category has spread rapidly through aesthetic clinics in the United States.
The evidence base is much thinner than the marketing suggests. There are no large, blinded, sham-controlled randomized trials of exosomes for pattern hair loss in humans. The FDA has issued public warnings about unapproved exosome products and has classified injectable exosomes as biological drug products that require FDA approval before clinical use. This category is best understood as preliminary and not yet supported by the level of evidence that would justify replacing or supplementing established medications.
Peptides (GHK-Cu and others)
Copper peptide GHK-Cu, originally identified for its role in wound healing, has been marketed for hair growth in topical formulations for years. The proposed mechanism is improved follicle environment through anti-inflammatory and pro-angiogenic effects. The clinical evidence in humans is limited to small studies, mostly without sham controls. Other "biomimetic peptides" sold in scalp serums have even less data. Peptides may have a modest supportive role for some patients, but they are not credibly a replacement for medication-level treatments, and the effect sizes claimed in marketing materials are typically not matched by published trials.
Microneedling
Microneedling, using a roller or pen device with fine needles to create controlled micro-injuries in the scalp, has accumulated reasonable evidence as an adjunct to topical minoxidil. The most-cited trial randomized 100 men with pattern hair loss to minoxidil alone or minoxidil plus weekly microneedling for 12 weeks, and showed a substantially larger hair count increase in the combination group (Dhurat et al., Int J Trichology, 2013). Subsequent trials have been smaller and more variable, but the direction of the signal is consistent. This is closer to "established adjunct" than "experimental."
A standalone use of microneedling without medication is less well-supported. The plausible role is layered on top of an existing regimen rather than as a replacement.
Next-generation topical anti-androgens
Several pharmaceutical companies are developing topical anti-androgens designed to act locally on scalp follicles without the systemic effects of oral finasteride or dutasteride. Clascoterone is a topical androgen receptor antagonist already FDA-approved for acne under a different brand and indication; a scalp formulation has been studied for pattern hair loss in phase 2 trials reported by the manufacturer, with phase 3 development ongoing. Pyrilutamide (GT20029) is another topical androgen receptor antagonist in phase 3 development in China and the United States.
If either of these reaches FDA approval for pattern hair loss with a clean safety profile, it would meaningfully expand the topical options available to patients, especially those who cannot tolerate oral medications. The honest current status is "in late-stage trials, not yet available, results promising but not finalized."
PP405 and the mitochondrial energy hypothesis
PP405 is a topical small molecule developed by Pelage Pharmaceuticals based on academic research at UCLA into how lactate metabolism affects hair follicle stem cell activation. Early-phase trial results reported by the company have generated press coverage. The candidate is still at an early clinical stage. As with all early-phase compounds, the gap between phase 2 topline numbers and broad patient access is years and many decisions away. It is reasonable to be cautiously interested without rearranging your current treatment around it.
Verteporfin and wound-healing-based approaches
Some of the most interesting basic-science research in recent years has come from the wound-healing field, where investigators have shown that blocking certain mechanotransduction pathways during wound repair can lead to skin regeneration rather than scarring, including hair follicle regeneration in mice (Mascharak et al., Science, 2021). Verteporfin, an existing drug used in ophthalmology, has been tested in this context. Translation to a usable hair loss treatment is not imminent. This is a category to watch in basic research rather than something to act on.
How to think about adding any of these
The pattern across most of these categories is the same. Real biology, plausible mechanisms, encouraging early signals, and a long way still to go before any one of them is ready to displace the existing standard of care. A few reasonable principles for thinking about an experimental treatment:
- If a treatment is being offered today at a high price by a clinic and is not FDA-approved for the condition it is being sold to treat, the burden of proof is on the seller, not on you.
- "FDA-cleared" and "FDA-approved" are not the same thing. Clearance is a lower bar that does not require demonstrated efficacy.
- An adjunct to existing medications is a different proposition from a replacement for them. The risk-benefit math is more favorable for adjunct use.
- Time matters. Most pattern hair loss treatments take 6 to 12 months to show response. A few months on an experimental treatment is not a meaningful test.
If you are weighing whether and how to update your regimen, the Curekey hair assessment is one way to get a U.S.-licensed physician to review your situation and recommend an evidence-based plan rather than reaching for whatever is generating the most marketing attention this year.
Related reading
- How minoxidil treats hair loss: the topical with the strongest randomized evidence in pattern hair loss.
- How finasteride treats hair loss: the oral with the largest published effect sizes.
- How dutasteride treats hair loss: the dual-isozyme alternative for patients whose response to finasteride is incomplete.
- Red light therapy (LLLT) for hair loss: an honest look at a different category of adjunct device.
- How it works: what a Curekey assessment and physician review look like.
